Pushing for a New Era in Cardiology: Matt Killeen, PhD
Matt Killeen, PhD, chief scientific officer at Renovacor, shares updates on the company's lead candidate, REN-001, an adeno-associated viral vector serotype 9-based gene therapy for the treatment of BAG3-associated dilated cardiomyopathy.
"Given the fact that today's therapies for heart failure and inherited heart diseases really just work around the edges, patients can quickly find themselves exhausting current treatment options and facing the prospect of procedures." —Matt Killeen, PhD, Chief Scientific Officer, Renovacor
As more and more patients become empowered to take control of their individual health, there is increasing emphasis on cardiac screening and genetic testing. One form of genetically driven heart failure, BAG3-associated dilated cardiomyopathy (DCM), has become an area of focus, as there are currently no commercially available targeted treatments.
Researchers at Renovacor are hoping to change that with REN-001, an adeno-associated viral (AAV) vector serotype 9-based gene therapy for the treatment of DCM.
Matt Killeen, PhD, chief scientific officer at Renovacor, joins CGTL to share updates on REN-001, which is in late stage preclinical development, and other candidates in the pipeline, as well as to shed some light on why the company chose to focus on this genetic form of heart disease.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
